全文获取类型
收费全文 | 6432篇 |
免费 | 709篇 |
国内免费 | 224篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 62篇 |
妇产科学 | 36篇 |
基础医学 | 604篇 |
口腔科学 | 65篇 |
临床医学 | 721篇 |
内科学 | 669篇 |
皮肤病学 | 69篇 |
神经病学 | 256篇 |
特种医学 | 389篇 |
外国民族医学 | 16篇 |
外科学 | 864篇 |
综合类 | 1274篇 |
现状与发展 | 11篇 |
预防医学 | 378篇 |
眼科学 | 100篇 |
药学 | 708篇 |
9篇 | |
中国医学 | 384篇 |
肿瘤学 | 688篇 |
出版年
2024年 | 39篇 |
2023年 | 127篇 |
2022年 | 369篇 |
2021年 | 424篇 |
2020年 | 420篇 |
2019年 | 255篇 |
2018年 | 256篇 |
2017年 | 263篇 |
2016年 | 227篇 |
2015年 | 353篇 |
2014年 | 467篇 |
2013年 | 372篇 |
2012年 | 397篇 |
2011年 | 424篇 |
2010年 | 261篇 |
2009年 | 261篇 |
2008年 | 266篇 |
2007年 | 293篇 |
2006年 | 285篇 |
2005年 | 244篇 |
2004年 | 183篇 |
2003年 | 172篇 |
2002年 | 189篇 |
2001年 | 136篇 |
2000年 | 129篇 |
1999年 | 182篇 |
1998年 | 69篇 |
1997年 | 72篇 |
1996年 | 58篇 |
1995年 | 46篇 |
1994年 | 31篇 |
1993年 | 21篇 |
1992年 | 21篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 8篇 |
排序方式: 共有7365条查询结果,搜索用时 15 毫秒
991.
原发性肝癌病因为多因素体亏虚,为七情所伤,肝气郁结,阻滞气机,致气滞不畅导致肝失疏泄,日久导致血行不畅而成血瘀,或由劳倦过度伤脾导致脾不健运,湿邪内停,外有湿热毒邪内侵,过嗜烟酒而化湿生热,导致气滞血瘀,痰凝毒结于肝,日久更伤正气,正不胜邪又助长积块生长,循环往复,停于腹中,本虚标实,渐形成臌胀或积聚,终致肝积之证。原发性肝癌分为三型:气滞血瘀、湿热蕴结、气阴两虚。临床当根据具体症状进行个体处方以缓解患者痛苦,不适合做肝切除或长期放化疗的患者可从中医整体出发辨证论治,减轻临床症状及放化疗所带来的副作用。 相似文献
992.
993.
Guanzhong Zhang Zhaozhe Liu Tao Han Fang Guo Qingqing Sun Yanan Ge Yaling Han Xiaodong Xie 《中德临床肿瘤学杂志》2014,(11):528-531
We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71-79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, dl-5, combined with cisplatin 20 mg/m^2 dl-3 or carbopiatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results:After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), and 3 cases had progression of disease (PD). The objective response rate was 65.6% (21/32), disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of 1/11 leukopenia and gastrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC. 相似文献
994.
Jianfei Guo Zhaozhe Liu Guojing Zhang Tao Han Fang Guo Yaling Han Xiaodong Xie 《中德临床肿瘤学杂志》2014,(12):555-559
Objective: The aim of this study was to evaluate the safety and efficiency of combination of trastuzumab and chemotherapy as first line regimen in Her-2 overexpressing metastatic breast cancer (MBC) patients. The primary endpoint was overall response rate (ORR) and the second endpoint was clinical benefit rate (CBR) and toxcities. Methods: Estrogen recep- tor (ER) (-), progesterone receptor (PR) (-), Her-2 (+++) patients were included in the study. 126 eligible patients were divided into 2 groups, 51 of them were assigned to the Herceptin group (H group) and 75 of them were assigned to the Control group (C group). They were treated by commonly used chemotherapy regimens with or without trastuzumab. Results: Response rate (RR) of the H group and the C group were 51.0% and 24.0% separately, and the difference were statistically significant (P 〈 0.05). CBR of the two groups were 76.4% (H group) and 64.0% (C group), had significant difference (P 〈 0.05). Complete response rate (CRR) of the two groups were 21.5% and 6.6%, there were no significant difference between the two groups (P = 0.055). Grade 3-4 cardiac toxicity were recorded in 9 patients with trastuzumab plus chemotherapy (17.6%) and 4 patients with chemotherapy (5.4%), with no statistical significance (P = 0.054). In the subgroup of antharcycline-containing regimens, Grade 1-4 cardiac toxicity occurred in 9 patients in the trasutuzumab combining with antharcycline-containing regimens arm [herceptin plus anthracyciine contained chemotherapy (H + ACCT arm; 40.9%, g/22)], and 4 patients in the antharcycline- containing chemotherapy arm (ACCT arm; 12.5%, 4/32). There was statistical significant difference between the two arms (P 〈 0.05). Grade 3--4 cardiac toxicity, the occurance rates were 18.1% (4/22) in H + ACCT arm and 6.3% (2/32) in ACCT arm, and there was no significant statistical difference (P = 0.352). Grade 3-4 granulocytopenia 相似文献
995.
Objective:The aim of the study was to investigate the relationship between expressions of estrogen receptor (ER), progesterone receptor (PR) and gender, age, tumor size, lymph node metastasis, capsular invasion and histological type of dif erentiated thyroid carcinoma (DTC). Methods:Seventy cases of DTC who received surgery in our hospital (No. 401 Hospital of People’s Liberation Army, Qingdao, China) between January 2008 and December 2011 were selected. Among them, 61 cases were papil ary carcinoma and 9 cases were fol icular carcinoma. Twenty cases were normal thyroid tissue adjacent to the tumor which was used as control. Immunohistochemical SP method was employed to detect the expression of ER and PR. Results:The positive rates of ER and PR in tumor tissues of DTC patients were 21.4%(15/70) and 31.4%(22/70), respectively, and no expression of ER or PR were founded in normal thyroid tissue (P<0.01). The expressions of ER and PR were related to the lymph node metastasis and capsular invasion (χ2=16.913 and 6.327, P<0.05;χ2=7.516 and 12.727, P<0.05). No relationship was observed between the expressions of ER/PR and gender, age, and histological type (P>0.05) of DTC patients. Conclusion:The expression levels of ER and PR in the tumor tissue of DTC patients were higher than those in the normal thyroid tissue nearby the tumor. Therefore, ER and PR expression might be clinical markers for DTC and its prognosis. 相似文献
996.
目的:探讨沉默RABGEF1基因对人卵巢癌细胞(SK-OV-3细胞)增殖的影响.方法:通过小干扰RNA技术沉默SK-OV-3细胞的RABGEF1基因表达,用实时荧光定量RT-PCR法鉴定细胞内RABGEF1基因的表达水平,培养RABGEF1基因被沉默的SK-OV-3细胞,计数不同时间点的细胞数,分析RABGEF1基因对人卵巢癌细胞增殖的影响.结果:实时荧光定量RT-PCR法检测显示所构建的4个siRNA表达载体对RABGEF1基因表达的沉默率分别为52.5%、58.1%、76.2%和87.7%.将RABGEF1基因表达沉默率为87.7%的SK-OV-3细胞继续培养,计数显示细胞数目较未沉默基因减少(P<0.05).结论:应用RNAi技术沉默RABGEF1基因可抑制SK-OV-3细胞的增殖,提示RABGEF1基因可能参与卵巢癌的发生发展. 相似文献
997.
998.
附子治疗痛类方中附子所治之痛,皆阳虚阴凝为患,附子补五脏之阳、壮命门之火,阳振阴散,其痛自止,配伍不同类药物,以达到针对主症,旁疗兼症之效。力求一药多能,综合发挥作用;重视人体生理,除邪先护正,祛邪留途径。 相似文献
999.
目的探讨清心解毒汤治疗邪毒侵心型病毒性心肌炎的疗效。方法采用前瞻性研究方法,选取我院2013年1月-6月收治的病毒性心肌炎患者160例,随机分为治疗组与对照组,各80例,治疗组给予清心解毒汤(麻黄、杏仁、生石膏、黄芩等,2次/d,200 mL/次),对照组给予常规西医对症治疗(卧床休息、抗病毒及调整免疫等常规对症治疗)。结果治疗组总有效率为86.25%,高于对照组的75.00%,差异有统计学意义(P<0.05);治疗组显效率为40.00%,高于对照组的30.00%(P<0.05);2组治疗后SV、CO和EF均高于治疗前(P<0.05);治疗组治疗后SV、CO和EF分别为(61.33±7.28)mL、(4.50±0.61)L/min和(55.01±6.64)%,均高于对照组(P<0.05);2组治疗后CK、CKMB、AST和LDH均低于治疗前(P<0.05);治疗组治疗后CK、CKMB、AST和LDH分别为(80.30±10.62)u/L、(18.61±5.69)u/L、(31.47±4.92)u/L和(92.42±10.73)u/L,均低于对照组(P<0.05)。结论清心解毒汤可以减轻心脏损害程度,治疗热毒侵心型病毒性心肌炎。 相似文献